Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companion diagnostics trend will make Rx look at in-house Dx anew

This article was originally published in Clinica

Executive Summary

Medium-sized and niche players – more than global concerns – have been driving most of the IVD industry’s engagement with pharma on joint companion diagnostics (CDx) projects so far. But with personalised medicine increasingly ingrained in the healthcare business psyche, it is likely that the pharma sector will henceforth exploit the emerging business opportunities most keenly. A new report from PwC describes the rationale behind this. Ashley Yeo reports

Topics

UsernamePublicRestriction

Register

MT098384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel